Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Up 269.6% in October

Vaccinex, Inc. (NASDAQ:VCNX) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 127,500 shares, a growth of 269.6% from the October 15th total of 34,500 shares. Currently, 9.1% of the shares of the company are sold short. Based on an average daily volume of 92,300 shares, the short-interest ratio is currently 1.4 days.

Hedge Funds Weigh In On Vaccinex

A hedge fund recently raised its stake in Vaccinex stock. AIGH Capital Management LLC raised its position in shares of Vaccinex, Inc. (NASDAQ:VCNX) by 86.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 108,958 shares of the company’s stock after purchasing an additional 50,593 shares during the quarter. AIGH Capital Management LLC owned about 6.90% of Vaccinex worth $707,000 as of its most recent SEC filing. Institutional investors own 50.11% of the company’s stock.

Vaccinex Price Performance

Shares of NASDAQ VCNX traded up $0.13 during midday trading on Tuesday, hitting $3.35. 18,399 shares of the company’s stock were exchanged, compared to its average volume of 55,236. Vaccinex has a twelve month low of $1.39 and a twelve month high of $13.16. The firm has a market cap of $5.79 million, a P/E ratio of -0.05 and a beta of 0.98. The stock’s 50 day moving average price is $3.72 and its 200-day moving average price is $5.22.

Vaccinex (NASDAQ:VCNX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($3.10) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million during the quarter.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.